L
Lian Dong
Researcher at United States Department of the Army
Publications - 11
Citations - 1706
Lian Dong is an academic researcher from United States Department of the Army. The author has contributed to research in topics: Ebola virus & Virus. The author has an hindex of 10, co-authored 11 publications receiving 1495 citations. Previous affiliations of Lian Dong include United States Army Medical Research Institute of Infectious Diseases.
Papers
More filters
Journal ArticleDOI
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.
I-Chueh Huang,Charles C. Bailey,Jessica L. Weyer,Sheli R. Radoshitzky,Michelle M. Becker,Jessica J. Chiang,Abraham L. Brass,Asim A. Ahmed,Xiaoli Chi,Lian Dong,Lindsay E. Longobardi,Dutch Boltz,Jens H. Kuhn,Stephen J. Elledge,Sina Bavari,Mark R. Denison,Hyeryun Choe,Michael Farzan +17 more
TL;DR: IFITM proteins differentially restrict the entry of a broad range of enveloped viruses, and modulate cellular tropism independently of viral receptor expression, and indicate that IFITM-mediated restriction is localized to a late stage in the endocytic pathway.
Journal ArticleDOI
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Travis K. Warren,Jay Wells,Rekha G. Panchal,Kelly S. Stuthman,Nicole L. Garza,Sean A. Van Tongeren,Lian Dong,Cary Retterer,Brett P. Eaton,Gianluca Pegoraro,Shelley P. Honnold,Shanta Bantia,Pravin L. Kotian,Xilin Chen,Brian R. Taubenheim,Lisa S. Welch,Dena M. Minning,Y.S. Babu,William P. Sheridan,Sina Bavari +19 more
TL;DR: It is shown that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells, and exhibits broad-spectrum antiviral activity against numerous viruses.
Journal ArticleDOI
Advanced antisense therapies for postexposure protection against lethal filovirus infections
Travis K. Warren,Kelly L. Warfield,Jay Wells,Dana L. Swenson,Kelly S Donner,Sean A. Van Tongeren,Nicole L. Garza,Lian Dong,Dan V. Mourich,Stacy Crumley,Donald K. Nichols,Patrick L. Iversen,Sina Bavari +12 more
TL;DR: Administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30–60 min after infection, protects >60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeysagainst Lake Victoria Marburg virus (MARV) infection.
Journal ArticleDOI
Infectious Lassa Virus, but Not Filoviruses, Is Restricted by BST-2/Tetherin
Sheli R. Radoshitzky,Lian Dong,Xiaoli Chi,Jeremiah C. Clester,Cary Retterer,Kevin B. Spurgers,Jens H. Kuhn,Sarah J. Sandwick,Gordon Ruthel,Krishna P. Kota,Dutch Boltz,Travis K. Warren,Philip J. Kranzusch,Sean P. J. Whelan,Sina Bavari +14 more
TL;DR: The results demonstrate that BST-2 might be a broad antiviral factor with the ability to restrict release of a wide variety of human pathogens, however, at least filoviruses, RVFV, and CPXV are immune to its inhibitory effect.
Journal ArticleDOI
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
Sandra L. Bixler,Thomas M. Bocan,Jay Wells,Kelly S. Wetzel,Sean A. Van Tongeren,Lian Dong,Nicole L. Garza,Ginger Donnelly,Lisa H. Cazares,Jonathan E. Nuss,Veronica Soloveva,Keith A. Koistinen,Lisa S. Welch,Carol Epstein,Li Fang Liang,Dennis Giesing,Robert Lenk,Sina Bavari,Travis K. Warren +18 more
TL;DR: Favipiravir is a broad‐spectrum antiviral agent that has demonstrated efficacy against Ebola virus (EBOV) in rodents and in vivo efficacy against two filoviruses, EBOV and Marburg virus (MARV), and its pharmacokinetic profile is evaluated.